MC# 17-09 - A Phase I Study of Intra-peritoneal Cantrixil in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer

  • Agent(s): Cantrixil
  • Disease Type(s): Endometrial, Ovarian
  • Phase(s): I
  • Drug Classification(s): Targeted Therapy, Small Molecule
  • Molecular Target(s): Cancer Stem Cells

Mechanism of Action

Cantrixil is a small molecule inducer of both caspase-dependent and caspase-independent cell death.  It appears to be able to reduce or eliminate cancer stem cells that are the cause of disease recurrence.

Purpose

In this study, the sponsor and investigators want to learn:

  • How much Cantrixil can be given with an acceptable level of side effects
  • The effects of Cantrixil when given alone or when given with chemotherapy
  • How proteins that indicate the status of disease are affected with use of Cantrixil
  • How much Cantrixil is absorbed into the blood and how fast it is removed
Inclusion Criteria
  • Patients must have recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer. The original diagnosis must be verified by a histology report. All histological sub-types and all grades of disease are eligible to participate; grade, histological sub-type and breast cancer susceptibility gene (BRCA) status must be recorded at study entry.
  • Patients must be female and at least 18 years old.
  • Patients with malignant ascites are eligible to participate; paracentesis will be conducted before the administration of Cantrixil. Drainage of the maximum volume of ascites necessary for symptomatic relief should be performed according to local standard operating procedures before administration of Cantrixil.
  • Patients must have completed at least two (2) or more prior therapies (including adjuvant therapy) for their ovarian, Fallopian tube or primary peritoneal cancer prior to participation in the current study; all prior therapies must be recorded at baseline. Patients that have received prior intraperitoneal therapy are eligible for this study.
  • Patients must have platinum-resistant relapsed disease, platinum refractory disease, or have documented intolerance to platinum therapy. Patients will not be eligible based on rising CA-125 levels alone, patients must have other clinical symptoms (such as malignant ascites) or radiological tumour measurements that support disease recurrence or progression
  • At least 4 weeks must have passed from any previous therapy (6 weeks for bevacizumab, nitrosoureas or mitomycin C treatment) any toxicities from prior therapies must have resolved to less than or equal to CTCAE version 4.03 Grade 1 with the exception of alopecia, Grade 2 prior platinum-therapy related neuropathy and Grade 2 anaemia.
  • Patients must have a performance status of Eastern Cooperative Oncology Group (ECOG) 0 to 2 and, in the Investigator’s opinion, be able to complete at least a major part of the study.
  • Patients willing and able to undergo insertion of a port or catheter for intraperitoneal access; the type of port or catheter used will be at the discretion of the Investigator and will be recorded.
  • Patients with measurable or non-measurable disease may be enrolled; disease response will be measured according to RECIST version 1.1 criteria using contrast CT or MRI and CA-125 measurements.
  • Patients with acceptable hepatic and marrow function as defined below:
    • Absolute neutrophil count >1.5 x 109/L without myeloid growth factor support.
    • Platelets >100 x 109/L.
    • Total bilirubin; <2.5 times the institutional upper limit of normal (ULN).
    • Haemoglobin (Hb) of >10 g/dL; patients with Hb >9g/dL will be considered for this study if they have not received a transfusion or other bone marrow support. Patients with Hb >10 g/dL that have received a recent transfusion will only be eligible if there has been a wash-out period of 7 days for rhesus factor and 10 days for platelet transfusions, respectively.
    • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/ alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) ≤2.5 x institutional ULN if no demonstrable liver metastases or <5 x ULN in the presence of liver metastases.
    • Serum creatinine <1.5 x ULN.
    • Prothrombin time (PT) or international normalised ratio (INR) ≤1.5 x ULN and activated partial thromboplastin time (aPTT) ≤1.5 x ULN if not on anticoagulation treatment.
  • Patients willing and able to comply with all study requirements, including treatment timing and/or nature of required assessments and treatment t designated study centre.
  • Each participant must be adequately informed about the purpose of the study; potential benefits and risks; their right to refuse participation or to withdraw consent at any time; institutional affiliation and potential competing interests of the researcher; and sources of study funding and have signed and dated a written informed consent form.
Exclusion Criteria
  • Patients who have had chemotherapy, targeted therapies, biologic therapy, immunotherapy, or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C or bevacizumab) prior to entering the study.
  • Patients must not have had major surgery within 4 weeks prior to screening.
  • Patients may not have received any other investigational medicinal products (IMPs) or participated in any other interventional clinical research studies within 3 months of the first Cantrixil administration.
  • Patients receiving any medications or substances that are strong inhibitors or inducers of cytochrome P450 (CYP)1A2, CYP2B6 and CYP3A4 or those substances with narrow therapeutic index are not to be enrolled. These compounds are prohibited from screening until completion of end of therapy or first post- treatment follow-up visit. For a list of prohibited medications see the University of Indiana Clinical Pharmacology Department's P450 Drug Interaction Table (http://medicine.iupui.edu/clinpharm/ddis/main-table/). Note: the use of paclitaxel is allowed, but only 24 hours after Cantrixil administration.
  • Patients at high risk of bowel perforation are excluded, including but not limited to any one or more of the following;
    • Patients with a recent history (previous 12 months) of bowel obstruction prior to study entry.
    • Patients with CT scans that suggest invasion of bowel by tumour.
    • Patients with symptoms to suggest impending bowel obstruction.
    • Patients with prior whole abdominal radiotherapy.
    • Patients with chronic inflammatory bowel diseases such as Crohn's disease or ulcerative colitis.
  • Patients may not have uncontrolled or severe systemic diseases or psychiatric conditions, which in the Investigator’s opinion makes it unsafe for the patient to participate in the study or would hinder compliance with the protocol. Screening for chronic conditions is not required.
  • Patients who are pregnant, lactating, or unable to adopt adequate contraception; women of  childbearing  potential  must  have  a  negative  pregnancy  test  within 7 days prior to screening.
  • Patients with a known history of hepatitis B or C.
  • Patients known to have tested positive for human immunodeficiency virus (HIV).
  • Patients with a known hypersensitivity to or a serious reaction to benzopyrans are excluded.

Location

  • Dallas, TX - Mary Crowley Cancer Research - Medical City
More Info: https://www.clinicaltrials.gov/ct2/show/NCT02903771?term=cantrixil&rank=1

Contact Us About This Trial

Reach out to us by sharing your info in the form below or give us a call at 972-566-3000.

Re: MC# 17-09